FDA Approves REZZAYO — Melinta Therapeutics, LLC

On March 22, 2023, the FDA approved Melinta Therapeutics, LLC’s REZZAYO (rezafungin), an IV antifungal designated for candidemia and intra-abdominal infections, marking a significant entry into the market following industry consolidation. This pivotal approval intensifies competition in the esophageal candidiasis segment and strengthens Melinta’s pipeline amid ongoing challenges in the biopharma sector.